Arcutis Announces Successful Phase 3 Results for Roflumilast Cream 0.05% in Children with Atopic Dermatitis
This new data results from the pivotal INTEGUMENT-PED trial and met both its primary and secondary endpoints.
Smitht Arcutis Arcutis Biotherapeutics Arcutis Biotherapeautics Inc Drug Administration Worst Itch Numeric Scale Trial Evaluating
Source: hcplive.com